

January 26, 2023

Dear DME providers,

Coloplast wants to better understand Medicare billing and qualification requirements for A4353 (closed system catheter), specifically under the immunosuppression criteria. If you are a DME provider that offers A4353 to Medicare beneficiaries, we ask that you take an online survey:

[https://coloplastus.qualtrics.com/jfe/form/SV\\_cD4wrpGoaz1ghds](https://coloplastus.qualtrics.com/jfe/form/SV_cD4wrpGoaz1ghds)

***To eliminate duplication of responses, we ask that only one survey is completed per DME provider. Please submit your survey responses no later than Friday, February 3<sup>rd</sup>, 2023.***

Background: As you know under the Medicare guidelines a patient must meet one out of five criteria to qualify for A4353 under LCD L33803.

1. The beneficiary resides in a nursing facility,

**2. The beneficiary is immunosuppressed, for example (not all-inclusive):**

- on a regimen of immunosuppressive drugs post-transplant,
- has AIDS,
- on cancer chemotherapy,
- has a drug-induced state such as chronic oral corticosteroid use.

3. The beneficiary has radiologically documented vesico-ureteral reflux while on a program of intermittent catheterization,

4. The beneficiary is a spinal cord injured female with neurogenic bladder who is pregnant (for duration of pregnancy only),

5. The beneficiary has had distinct, recurrent urinary tract infections, while on a program of sterile intermittent catheterization with A4351/A4352 and sterile lubricant A4332, twice within the 12-month prior to the initiation of sterile intermittent catheter kits.

**Recently, the DME MAC council and directors acknowledged that the list of examples in the Urological Supplies LCD (L33803- #2 criteria) describe scenarios that could result in immunosuppression and is not an all-inclusive but rather represents common conditions likely to result in immunosuppression. Therefore, patients with high-level spinal cord injuries (higher than T3) will be considered for coverage when conducting medical reviews of Intermittent catheterization using a sterile intermittent catheter kit (A4353).**

Our objective is to better understand if DME providers are successfully billing Medicare for A4353 while using the #2 qualifying criteria of the Medicare Urological Policy (L33803). In order to do this, we ask that you take a quick survey, which should not take more than 5 minutes to complete.

If you choose to participate in this survey regarding billing Medicare for closed system intermittent catheters your answers will not be used or shared with third parties for any purposes. All information and answers will be processed, aggregated, or compiled anonymously. No personally identifying data will be asked or collected as part of the survey responses.

If you have any questions and/or concerns, please reach out to Anna Markiewicz at [usanma@coloplast.com](mailto:usanma@coloplast.com)